Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
Key Highlights
- ➤Phase 1b planned for up to 50 advanced cancer patients with solid tumors
- ➤PPCB reports PPC-001 proenzymes remained detectable without significant degradation in human blood
- ➤PPCB achieved recovery generally exceeding 85% after 60 minutes at room temperature
- ➤LC-MS methods successfully measured PPC-001 components in human serum and plasma
- ➤Immunogenicity assay feasibility work is underway for both PPC-001 proenzyme components
Expert Statements
Ralf Brandt, Research & Development Director of Propanc Biopharma
“Propanc continues to advance its analytical development activities in parallel with preparations for its Phase 1b First-In-Human study. The ongoing feasibility assessment of immunogenicity assays, together with the planned optimization of pharmacokinetic bioanalytical methods and stability testing, represents an important component of the Company's clinical development strategy.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“The work undertaken led by Dr Ralf Brandt, our R&D Director, his team, and our partner CRO is of a high standard and provides an excellent framework for our world-first study for PPC-001 in advanced cancer patients.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“PPC-001, a combination therapy consisting of two pancreatic proenzymes from naturally derived sources is a unique approach to cancer treatment which has the capacity to reverse the effects of cancer cell dissemination and recurrence.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“By undertaking these important bioanalytical activities, we are going to obtain great insight into the effects of PPC-001.”
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability testing, supporting preparations for the planned Phase 1b, First-In-Human study of the Company’s lead clinical candidate, PPC-001, in up to 50 advanced cancer patients with solid tumors.
“Propanc continues to advance its analytical development activities in parallel with preparations for its Phase 1b First-In-Human study,” said Dr. Ralf Brandt, Propanc’s Research & Development Director. “The ongoing feasibility assessment of immunogenicity assays, together with the planned optimization of pharmacokinetic bioanalytical methods and stability testing, represents an important component of the Company's clinical development strategy.”
Get started
Create a free account to read the full story.